Objective The purpose of this 24‐month phase III study was to examine structural preservation
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …

Objective To evaluate the safety and clinical efficacy of administering an anti–interleukin‐10
(anti–IL‐10) monoclonal antibody (mAb) to systemic lupus erythematosus (SLE) patients …

Clinical and laboratory manifestations and outcome of systemic lupus erythematosus (SLE)
may vary in different populations. A prospective multinational inception cohort should prove …

Objective To determine whether there is familial aggregation of systemic lupus erythematosus
(SLE) and/or other autoimmune diseases in SLE patients and to identify clinical …

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …

Objective. To estimate the prevalence of musculoskeletal (MSK) disorders and to describe
predicting variables associated with rheumatic diseases in 5 regions of México. Methods. This …

Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and
ethnic disparities. We report a large transancestral association study of SLE using Immunochip …

Several clinical indices have been proposed to measure disease activity in patients with
systemic lupus erythematosus. Only a few have been subjected to extensive analysis. We report …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …

BACKGROUND: This study was undertaken in order to identify the prevalence and factors
associated with depression in a group of patients with type 2 diabetes mellitus. METHODS: …